View All3 Potent Biotech Stocks That Could Pop on EarningsLike golf, investing in biotech stocks can be cruel game. As Michael A. Gayed explains, the pricing dynamic of individual biotech stocks will often follow the perceived successes — or failures — of drug trials and the multiple approval procedures enforced by regulatory agencies.Source: ©iStock.com/twilightproductionsThis Wild West mentality is primarily the […]
View All4 Biotech Stocks Poised to Jump 15%It’s been something of a lackluster week for the broad market — but biotech has really shined.Source: FlickrWhile the S&P 500 was up just 1.3% as of Wednesday afternoon, biotechs as a group outperformed, gaining nearly 2.5%.7 Small-Cap Healthcare Stocks Set to Soar
This sector is famous for being a volatile one, so timing […]
The Market Trend Model (http://bitly.com/M_Trend_Model) continues to hold its positive bias as the Nasdaq (http://scharts.co/1HAtavT) battles against the area around the5,000 level. Likewise, the S&P 500 (http://scharts.co/1b4JwQD) is in its own epic battle with the area around the 2,100 level. So far during the week the indexes have found support at their respective 20-day moving averages as earnings season has […]
The enticing if volatile biotechs continue to intrigue investors. Some of the stocks in the fast-growing sector are more alluring than many others, but make no mistake: Biotechs should not be ignored!“Biotech stocks are still in favor with investors for all the right reasons: constant M&A, solid clinical data, regulatory reviews, upcoming scientific conferences, selective stock picking, and technical support,” […]
Biotech has been one hot sector again in 2015. Two key biotech exchange traded funds are up 20% or so on average year-to-date. 247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to 100% was predicted for four biotech and specialty pharma stocks.Before just chasing these higher, investors should understand […]
Biotech has been one hot sector again in 2015. Two key biotech exchange traded funds are up 20% or so on average year-to-date. 247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to 100% was predicted for four biotech and specialty pharma stocks.Before just chasing these higher, investors should understand […]
Dear Reader,European stocks seem to have started the 10% correction I predicted. The German DAX Index is down circa 5.5% from its peak.European ‘periphery’ government bonds seem to have started the sell off I predicted. Spanish and Italian government bonds sold off hard during the past several weeks. I think the sell off will continue and even accelerate.I expect the […]
Study after study of the money managers who have had the best long term performance shows the same thing—-while the money managers made a lot of money over time, the average client lost money. This isn’t some sort of Ponzi scheme, it is because investors and advisers tend to buy into money managers or strategies when they are doing well […]
Related SGNT5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 YearsPorat To Google Just One Of The Week’s Top Management Changes; Here Are 7 MoreRelated IPXLFTC Requires Divestitures in Connection With Impax Laboratories Inc.’s Proposed Acquisition of CorePharma, LLCJPM Securities Picks Through Biotech News For WinnersMylan makes $205/share bid for Perrigo; Generic firms rally(Seeking Alpha)Shares of […]
Since reaching all-time highs on March 19, the three largest biotech exchange traded funds are off 4.4% with the SPDR S&P Biotech ETF (XBI) ranking as the worst offender of the trio with a loss of 5.7%.XBI’s recent struggles illustrate the ETF’s risk/reward proposition. As an equal-weight ETF, the $2.1 billion XBI is dependent on the largest biotech stocks, such […]
